Sight Sciences Q1 Revenue $19.7M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $19.7M, consensus $18.55M. "We delivered a strong start to 2026, with first quarter results reflecting a return to double-digit revenue growth, sustained gross margin strength, and disciplined operating expense and cash management," said Paul Badawi, Co-Founder and CEO of Sight Sciences. "Execution was solid across both segments, including a third consecutive quarter of revenue growth in Interventional Glaucoma and continued momentum in Interventional Dry Eye, where revenue nearly doubled sequentially. We remain focused on continued growth in combination-cataract procedures and activating standalone interventions in glaucoma, and accelerating growth and expanding access to reimbursed interventional TearCare treatments."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGHT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGHT
Wall Street analysts forecast SGHT stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 5.350
Low
6.00
Averages
9.35
High
12.00
Current: 5.350
Low
6.00
Averages
9.35
High
12.00
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sight Sciences Reports Strong Q1 2026 Earnings with Revenue Guidance Raise
- Revenue Growth Resurgence: Sight Sciences reported total revenue of $19.7 million in Q1 2026, reflecting a return to double-digit growth compared to the previous year, which enhances market confidence and lays a solid foundation for future development.
- Dry Eye Business Boost: The company generated $1.4 million in revenue from dry eye customers and raised its dry eye revenue guidance by an additional $1 million at the midpoint, indicating increasing commercial traction in this segment.
- Litigation Progress: The court upheld a judgment against Alcon for willful infringement, awarding approximately $55 million and establishing ongoing royalties of 10% on future Hydrus sales, although no cash has been received to date, which may impact the company's cash flow and financial stability.
- Optimistic Outlook: The company raised its 2026 revenue guidance to $83 million to $89 million while reaffirming adjusted operating expense guidance of $93 million to $96 million, demonstrating management's confidence in future growth and commitment to cost control.
See More
Sight Sciences Q1 Earnings Beat Expectations with Revenue Guidance Raised
- Earnings Performance: Sight Sciences reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.07, yet achieved revenue of $19.7 million, reflecting a 12.6% year-over-year increase and exceeding estimates by $1.15 million, indicating resilience in market performance.
- Revenue Guidance Increase: The company raised its 2026 revenue guidance to a range of $83 million to $89 million, representing a growth of 7% to 15% compared to 2025, showcasing confidence in future growth, particularly in the glaucoma and dry eye segments.
- Segment Growth: The revenue guidance includes $77 million to $81 million from the Interventional Glaucoma segment, reflecting a growth of 2% to 7%, and $6 million to $8 million from the Interventional Dry Eye segment, a significant increase from $1.6 million in 2025, highlighting the company's market expansion capabilities.
- Operating Expense Guidance: Sight Sciences reaffirmed its adjusted operating expenses guidance for 2026 at $93 million to $96 million, an increase of 6% to 9% compared to 2025, primarily due to targeted investments in market access and commercial resources aimed at scaling the reimbursed dry eye market.
See More
Sight Sciences Releases Annual Sustainability Report Highlighting Key Initiatives
- Environmental Footprint Reduction: Sight Sciences achieved over a 20% reduction in emissions in 2025, demonstrating the company's ongoing efforts to minimize environmental impact while committing to future emissions reporting and compliance with regulations that promote low GHG emission technologies.
- Social Responsibility Commitment: The company donated to 24 programs supporting indigent care across 24 countries from 2023 to 2025, reflecting its emphasis on community engagement and employee well-being, thereby enhancing its corporate social responsibility profile.
- Employee Diversity: As of December 31, 2025, Sight Sciences employed 187 people globally, with women comprising 56% of the workforce, showcasing the company's proactive efforts in promoting gender equality and diversity within its ranks.
- Transparent Governance Framework: The company disclosed its governance framework and compliance programs, including oversight of cybersecurity and responsible AI use, emphasizing its commitment to transparency and accountability in corporate governance.
See More
Sight Sciences Prevails in Patent Infringement Case Against Alcon
- Court Ruling Outcome: The U.S. District Court for Delaware upheld the jury's finding of willful infringement by Alcon, ordering them to pay $34 million in damages, which underscores Sight Sciences' robust intellectual property protection capabilities.
- Ongoing Revenue Assurance: The ruling mandates that Alcon pay a 10% ongoing royalty on Hydrus sales until November 10, 2028, providing Sight Sciences with a stable revenue stream and enhancing its financial stability moving forward.
- Damages Breakdown: The $34 million in damages includes $5.5 million in lost profits and $28.5 million in royalties, reflecting the strong market performance of the Hydrus product and its positive impact on Sight Sciences' financials.
- Legal Fee Expectations: Sight Sciences anticipates a $5.4 million success fee to Cooley LLP, which will be recorded as operating expenses but excluded from non-GAAP adjusted operating expenses, highlighting the company's commitment to legal matters and its implications for future investments.
See More
SIGHT SCIENCES: 10% ROYALTY ON HYDRUS REVENUE GRANTED UNTIL NOVEMBER 10, 2028
Award Announcement: A significant award has been granted to the organization for its contributions to science.
Revenue Share: The organization will receive 10% of the revenue generated from Hydrus through November 10, 2028.
See More
SIGHT SCIENCES: $34 MILLION IN MONETARY DAMAGES AWARDED, ALONG WITH ADDITIONAL DAMAGES AND INTEREST, FOR PRIOR INFRINGEMENT
Monetary Damages Awarded: A total of $34 million in monetary damages has been awarded for past infringement.
Supplemental Damages and Interest: Additional supplemental damages and interest have also been included in the award.
See More
Sight Sciences Reports Strong Q1 2026 Earnings with Revenue Guidance Raise
- Revenue Growth Resurgence: Sight Sciences reported total revenue of $19.7 million in Q1 2026, reflecting a return to double-digit growth compared to the previous year, which enhances market confidence and lays a solid foundation for future development.
- Dry Eye Business Boost: The company generated $1.4 million in revenue from dry eye customers and raised its dry eye revenue guidance by an additional $1 million at the midpoint, indicating increasing commercial traction in this segment.
- Litigation Progress: The court upheld a judgment against Alcon for willful infringement, awarding approximately $55 million and establishing ongoing royalties of 10% on future Hydrus sales, although no cash has been received to date, which may impact the company's cash flow and financial stability.
- Optimistic Outlook: The company raised its 2026 revenue guidance to $83 million to $89 million while reaffirming adjusted operating expense guidance of $93 million to $96 million, demonstrating management's confidence in future growth and commitment to cost control.
See More
Sight Sciences Q1 Earnings Beat Expectations with Revenue Guidance Raised
- Earnings Performance: Sight Sciences reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.07, yet achieved revenue of $19.7 million, reflecting a 12.6% year-over-year increase and exceeding estimates by $1.15 million, indicating resilience in market performance.
- Revenue Guidance Increase: The company raised its 2026 revenue guidance to a range of $83 million to $89 million, representing a growth of 7% to 15% compared to 2025, showcasing confidence in future growth, particularly in the glaucoma and dry eye segments.
- Segment Growth: The revenue guidance includes $77 million to $81 million from the Interventional Glaucoma segment, reflecting a growth of 2% to 7%, and $6 million to $8 million from the Interventional Dry Eye segment, a significant increase from $1.6 million in 2025, highlighting the company's market expansion capabilities.
- Operating Expense Guidance: Sight Sciences reaffirmed its adjusted operating expenses guidance for 2026 at $93 million to $96 million, an increase of 6% to 9% compared to 2025, primarily due to targeted investments in market access and commercial resources aimed at scaling the reimbursed dry eye market.
See More
Sight Sciences Releases Annual Sustainability Report Highlighting Key Initiatives
- Environmental Footprint Reduction: Sight Sciences achieved over a 20% reduction in emissions in 2025, demonstrating the company's ongoing efforts to minimize environmental impact while committing to future emissions reporting and compliance with regulations that promote low GHG emission technologies.
- Social Responsibility Commitment: The company donated to 24 programs supporting indigent care across 24 countries from 2023 to 2025, reflecting its emphasis on community engagement and employee well-being, thereby enhancing its corporate social responsibility profile.
- Employee Diversity: As of December 31, 2025, Sight Sciences employed 187 people globally, with women comprising 56% of the workforce, showcasing the company's proactive efforts in promoting gender equality and diversity within its ranks.
- Transparent Governance Framework: The company disclosed its governance framework and compliance programs, including oversight of cybersecurity and responsible AI use, emphasizing its commitment to transparency and accountability in corporate governance.
See More
Sight Sciences Prevails in Patent Infringement Case Against Alcon
- Court Ruling Outcome: The U.S. District Court for Delaware upheld the jury's finding of willful infringement by Alcon, ordering them to pay $34 million in damages, which underscores Sight Sciences' robust intellectual property protection capabilities.
- Ongoing Revenue Assurance: The ruling mandates that Alcon pay a 10% ongoing royalty on Hydrus sales until November 10, 2028, providing Sight Sciences with a stable revenue stream and enhancing its financial stability moving forward.
- Damages Breakdown: The $34 million in damages includes $5.5 million in lost profits and $28.5 million in royalties, reflecting the strong market performance of the Hydrus product and its positive impact on Sight Sciences' financials.
- Legal Fee Expectations: Sight Sciences anticipates a $5.4 million success fee to Cooley LLP, which will be recorded as operating expenses but excluded from non-GAAP adjusted operating expenses, highlighting the company's commitment to legal matters and its implications for future investments.
See More
SIGHT SCIENCES: 10% ROYALTY ON HYDRUS REVENUE GRANTED UNTIL NOVEMBER 10, 2028
Award Announcement: A significant award has been granted to the organization for its contributions to science.
Revenue Share: The organization will receive 10% of the revenue generated from Hydrus through November 10, 2028.
See More
SIGHT SCIENCES: $34 MILLION IN MONETARY DAMAGES AWARDED, ALONG WITH ADDITIONAL DAMAGES AND INTEREST, FOR PRIOR INFRINGEMENT
Monetary Damages Awarded: A total of $34 million in monetary damages has been awarded for past infringement.
Supplemental Damages and Interest: Additional supplemental damages and interest have also been included in the award.
See More
